The ME Association, a national charity based in Gawcott, Bucks, has announced its investment in a major clinical trial in Canada to study the effects of low-dose naltrexone (LDN) on ME, chronic fatigue syndrome (CFS) and Long Covid.
The trial, led by Dr. Luis Nacul at the University of British Columbia, will investigate whether LDN can alleviate symptoms like fatigue, pain, and sleep disturbances while reducing inflammation.
With no current cure for ME/CFS or Long Covid, the study aims to provide crucial evidence on LDN’s potential benefits. If successful, it could pave the way for wider use of the drug in the UK. Dr. Charles Shepherd, the ME Association’s medical advisor, emphasized the urgent need for effective treatments, highlighting the significant impact these conditions have on individuals and healthcare systems.
The double-blind, placebo-controlled trial is set to conclude by December 2025, with results expected in early 2026.
The ME Association in Bucks hopes this research will contribute to better treatment options for those suffering from these debilitating conditions.
Waddesdon Hairdressers Take on Charity Skydive in Memory of Aylesbury Schoolgirl
Angels Den 2026: a ceremony summary
Two men jailed in separate cases in latest Aylesbury drug offence sentencings
Revised plans for unmanned Cricket Box in High Wycombe submitted to Bucks Council
Bucks Council leader explains importance of recently launched budget consultation
Co-founder of famous music club friars to shave his head for charity
University of Buckingham encouraging everyone in the county to consider apprenticeships
Bucks MPs raise local issues in Parliament
